Business Context and Reporting Period
Park Ha Biological Technology Co., Ltd., a foreign private issuer, filed this Form 6-K on September 11, 2026, to disclose a private placement transaction. The company is headquartered in Wuxi, Jiangsu Province, People's Republic of China.
Key Financial Metrics and Transaction Details
The filing details a Private Investment in Public Equity (PIPE) transaction closed on September 11, 2026. Key metrics include:
- Shares Issued: 1,080,000 Class A ordinary shares.
- Share Price: $2.75 per Class A ordinary share.
- Warrants Issued: 1,845,452 warrants to purchase Class A ordinary shares.
- Warrant Terms: Exercise price of $1.10 per share; each warrant exercisable for 2.5 shares; five-year term; exercisable immediately.
- Gross Proceeds: Approximately $2,970,000 (before offering expenses).
- Use of Proceeds: General working capital and corporate purposes.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
This filing represents a material capital event rather than a periodic financial update. The issuance of new shares and warrants will result in immediate dilution to existing shareholders. The filing does not provide comparative financial data against prior periods.
Outlook, Risks, and Contingencies
Management intends to utilize the net proceeds for general working capital. The securities were offered and sold in offshore transactions to non-U.S. persons in reliance upon Regulation S. Consequently, the Class A Ordinary Shares, Warrants, and Warrant Shares are not registered under the Securities Act of 1933 and may not be offered, sold, or transferred in the United States or to U.S. persons absent registration or an available exemption. The filing notes customary representations, warranties, and indemnification obligations within the Securities Purchase Agreement.
Investor Verification Checklist
- Verify the exact amount of offering expenses to determine net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant Agreement (Exhibit 4.1) for specific covenants and anti-dilution mechanics.
- Confirm the current authorized share capital to assess the impact of the new issuance on total outstanding shares.
- Check for any subsequent filings regarding the utilization of proceeds or changes in the company's financial position.